Literature DB >> 11408240

Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.

J Lennerstrand1, D K Stammers, B A Larder.   

Abstract

We have found a close correlation between viral stavudine (d4T) resistance and resistance to d4T-triphosphate at the human immunodeficiency virus type 1 reverse transcriptase (RT) level. RT from site-directed mutants with 69S-XX codon insertions and/or conventional zidovudine resistance mutations seems to be involved in an ATP-dependent resistance mechanism analogous to pyrophosphorolysis, whereas the mechanism for RT with the Q151M or V75T mutation appears to be independent of added ATP for reducing binding to d4T-triphosphate.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11408240      PMCID： PMC90617          DOI： 10.1128/AAC.45.7.2144-2146.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Stavudine resistance: an update on susceptibility following prolonged therapy.

Authors:  P F Lin; C J González; B Griffith; G Friedland; V Calvez; F Ferchal; R F Schinazi; D H Shepp; A B Ashraf; M A Wainberg; V Soriano; J W Mellors; R J Colonno
Journal:  Antivir Ther       Date:  1999

3.  Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.

Authors:  P F Lin; H Samanta; R E Rose; A K Patick; J Trimble; C M Bechtold; D R Revie; N C Khan; M E Federici; H Li
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

4.  A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.

Authors:  P R Meyer; S E Matsuura; A M Mian; A G So; W A Scott
Journal:  Mol Cell       Date:  1999-07       Impact factor: 17.970

5.  Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates.

Authors:  P R Meyer; S E Matsuura; R F Schinazi; A G So; W A Scott
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

7.  Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.

Authors:  P Kellam; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

8.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors:  T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

9.  Crystals of HIV-1 reverse transcriptase diffracting to 2.2 A resolution.

Authors:  D K Stammers; D O Somers; C K Ross; I Kirby; P H Ray; J E Wilson; M Norman; J S Ren; R M Esnouf; E F Garman
Journal:  J Mol Biol       Date:  1994-09-30       Impact factor: 5.469

10.  Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.

Authors:  S F Lacey; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191
View more
  12 in total

1.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

2.  Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants.

Authors:  Peter R Meyer; Anthony J Smith; Suzanne E Matsuura; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 3.  Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:  Mark A Winters; Thomas C Merigan
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.

Authors:  Johan Lennerstrand; Chung K Chu; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

Review 5.  Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.

Authors:  Jorge L Martinez-Cajas; Mark A Wainberg
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

Review 7.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

8.  Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation.

Authors:  Peter R Meyer; Johan Lennerstrand; Suzanne E Matsuura; Brendan A Larder; Walter A Scott
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.

Authors:  Paul L Boyer; Tomozumi Imamichi; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs.

Authors:  Kris Covens; Nathalie Dekeersmaeker; Yoeri Schrooten; Jan Weber; Dominique Schols; Miguel E Quiñones-Mateu; Anne-Mieke Vandamme; Kristel Van Laethem
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.